PYXS:NASDAQ, Pyxis Oncology, Inc.

PYXS stock overview

Pyxis Oncology, Inc. (PYXS:NASDAQ) closed at $1.58 on November 13, 2026, unchanged on the day. The stock trades 71.5% below its 52-week high of $5.55 and 53.4% above its 52-week low of $1.03. Over the past year, it lost 66.0%. Pyxis Oncology, Inc. is part of the Health Care sector.

Key figures

Price

$1.58

Day change

0.00%

Volume

358,462

Average volume

995,907

Market cap

188M+

52-week range

$1.03 – $5.55

50-day average

$2.36

200-day average

$2.16

Price action over the past year

In 252 trading sessions since November 13, 2025, PYXS closed higher on 119 days (47%). Its best day was May 6, 2026 (+25.68%) and its worst was December 18, 2025 (-48.66%). The stock moved 10% or more in a single session 28 times.

Recent signals

• Nov 14, 2026: Trading sideways between $1.58 and $1.70 over 14 days (Sideways scanner)
• Nov 6, 2026: News catalyst: Clinical Trial (News Catalysts scanner)
• Sep 30, 2026: Dropped 19.7% in a single session (Dips & Crashes scanner)
• Sep 8, 2026: Spiked to $4.15 on 1M+ shares (Spikes scanner)

PYXS news

• Nov 6, 2026: Pyxis Oncology Catalysts on Track With Upcoming Trial Results in Head, Neck Cancer Treatment, RBC Says
• Nov 5, 2026: Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO)
• Oct 28, 2026: Pyxis Oncology to Participate in Upcoming Investor Conferences
• Oct 27, 2026: Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
• Oct 2, 2026: Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
• Sep 30, 2026: Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
• Sep 29, 2026: Pyxis Oncology stock falls on public offering announcement
• Sep 29, 2026: Pyxis Oncology Announces Proposed Public Offering

About Pyxis Oncology, Inc.

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

Similar stocks

• KRRO:NASDAQ
• NEGG:NASDAQ
• RNAC:NASDAQ
• ACOG:NASDAQ
• WHWK:NASDAQ
• SLGL:NASDAQ
• ARTV:NASDAQ
• CGEN:NASDAQ

Find more stocks like PYXS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.